Citation Impact
Citing Papers
Differential Effects of Octreotide and Pasireotide on Somatostatin Receptor Internalization and Trafficking in Vitro
2008
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
2011
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
2011 Standout
Prognostic Significance of Somatic RET Oncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study
2007
Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma
2013
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
2014
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
2003 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma
2015
Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours
1999
Genotype-phenotype correlation in multiple endocrine neoplasia type 2
2012
Cancer treatment and survivorship statistics, 2022
2022 Standout
Hereditary hyperparathyroidism—a consensus report of the European Society of Endocrine Surgeons (ESES)
2015
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma
2005
Molecular imaging in drug development
2008 Standout
Early or prophylactic thyroidectomy in MEN 2/FMTC gene carriers: results in 71 thyroidectomized patients. The French Calcitonin Tumours Study Group (GETC)
1999
Randomized Study Comparing Carboplatin/Cyclophosphamide and Cisplatin/Cyclophosphamide as First-Line Treatment in Patients with Stage III/IV Epithelial Ovarian Cancer and Small Volume Disease
1997
Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy
2016
Separation of cathepsin A-like enzyme and the proteasome: evidence that lactacystin/β-lactone is not a specific inhibitor of the proteasome
2000 StandoutNobel
Peak Incidence of Pheochromocytoma and Primary Hyperparathyroidism in Multiple Endocrine Neoplasia 2: Need for Age-Adjusted Biochemical Screening
2013
Thyroid cancer
2016 Standout
Positron Emission Tomography Imaging of Cell Proliferation in Oncology
2003
Changes in risk factors and Tumor Node Metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin
2010
Identification of occult metastases of medullary thyroid carcinoma by pentagastrin‐stimulated intravenous calcitonin sampling followed by targeted surgery
2007
Contribution of platelets to tumour metastasis
2011 Standout
A comprehensive map of molecular drug targets
2016 Standout
Nedaplatin: a cisplatin derivative in cancer chemotherapy
2013
Cancer Metastasis: Building a Framework
2006 Standout
The Genetic Basis of Pheochromocytoma
2003
Head and neck cancer
2008 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Risk factors for bleeding in major abdominal surgery using heparin thromboprophylaxis
1997
Long‐term prognosis of medullary thyroid carcinoma
2008
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update
2013
Prospects of Remission in Medullary Thyroid Carcinoma According to Basal Calcitonin Level
2005
Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls
2008
Particular aspects of platinum compounds used at present in cancer treatment
2002
MEDULLARY THYROID CARCINOMA: A 20‐YEAR EXPERIENCE FROM A CENTRE IN SOUTH INDIA
2007
Sporadic Medullary Microcarcinoma of the Thyroid: A Retrospective Analysis of Eighty Cases
1998
Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma
2000
Molecular mechanisms of cisplatin resistance
2011 Standout
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
3D Slicer as an image computing platform for the Quantitative Imaging Network
2012 Standout
Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma
2011
External Beam Radiation Therapy for Thyroid Cancer
2008
Therapeutic potential of β-arrestin- and G protein-biased agonists
2010 StandoutNobel
The Timing of Total Thyroidectomy in RET Gene Mutation Carriers Could Be Personalized and Safely Planned on the Basis of Serum Calcitonin: 18 Years Experience at One Single Center
2011
New Equations to Estimate GFR in Children with CKD
2009 Standout
Polymer conjugates as anticancer nanomedicines
2006 Standout
Evolution of Surgical Treatment of Primary Hyperparathyroidism in Patients With Multiple Endocrine Neoplasia Type 2A
2010
Das medulläre Schilddrüsenkarzinom
2015
Advances in the management of hereditary medullary thyroid cancer
2004
Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome
2001
Cellular processing of platinum anticancer drugs
2005 Standout
High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation
2014
Prognostic Variables and Calcitonin in Medullary Thyroid Cancer
2005
Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer
2007
When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations?
2003
Advances and Challenges of Liposome Assisted Drug Delivery
2015 Standout
Prevention of VTE in Nonorthopedic Surgical Patients
2012 Standout
Novel germline mutation in the transmembrane region of RET gene close to Cys634Ser mutation associated with MEN 2A syndrome
2004
Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis
2018 StandoutNobel
Treatment of medullary thyroid carcinoma: an update.
2001
Parathyroid surgery in familial hyperparathyroid disorders*
2004
Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation
2008
Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma
2001
A Novel Point Mutation of theRETProtooncogene Involving the Second Intracellular Tyrosine Kinase Domain in a Family with Medullary Thyroid Carcinoma
2004
RET receptor signaling: Dysfunction in thyroid cancer and Hirschsprung's disease
2006
Identification of low-density platelet populations with increased reactivity and elevated α-granule content
2003 StandoutNobel
The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT
2009
Clinical development of platinum complexes in cancer therapy: an historical perspective and an update
1998
Microenvironmental regulation of metastasis
2008 Standout
Adjuvant external beam radiation for medullary thyroid carcinoma
2010
Neuroblastoma
2007 Standout
Theranostic Lipid Nanoparticles for Cancer Medicine
2015
Management of medullary thyroid carcinoma and MEN2 syndromes in childhood
2011
Predicting GFR in children and adults: A comparison of the Cockcroft-Gault, Schwartz, and Modification of Diet in Renal Disease formulas
2003
Pediatric Ethics Guidelines for Hereditary Medullary Thyroid Cancer
2011
Hereditary medullary thyroid cancer in Slovenia – genotype-phenotype correlations
2006
Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients
2003
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Consensus on management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI)
2015
Platelet Density Distribution in Essential Thrombocythemia
2010 StandoutNobel
Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.
1996
Medullary thyroid carcinoma
2004
Standards for PET Image Acquisition and Quantitative Data Analysis
2009
Determinants of life expectancy in medullary thyroid cancer: age does not matter
2006
Estimation of glomerular filtration rate in cancer patients
2001
Metaiodobenzylguanidine assessment of metastatic neuroblastoma: Observer dependency and chemosensitivity evaluation
2000
Multiple endocrine neoplasia type 2 andRET: from neoplasia to neurogenesis
2000
Very early detection of RET proto‐oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children
2002
Medullary thyroid carcinoma
2000
Management of advanced medullary thyroid cancer
2015
Platinum drugs in the treatment of non-small-cell lung cancer
2002
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Prognosis of medullary thyroid carcinoma
2006
Evaluation of semi‐quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma
2006
Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A (codon 634) and 2B
2009
Selective uptake of boronated low-density lipoprotein in melanoma xenografts achieved by diet supplementation
1996
Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging
2003
Body Surface Area as a Determinant of Pharmacokinetics and Drug Dosing
2001
Tumours of familial origin in the head and neck
2006
The dawning era of polymer therapeutics
2003 Standout
Matrix metalloproteinases and tumor metastasis
2006 Standout
Multiple Endocrine Neoplasia Type 2
2003
Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism
2011
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
2015 Standout
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
2009 Standout
A New Germline Point Mutation in Ret Exon 8 (Cys 515 Ser) in a Family with Medullary Thyroid Carcinoma
2008
Inherited Medullary Thyroid Cancer and the Duty to Warn: Revisiting Pate v. Threlkel in Light of HIPAA
2005
Lymph node metastases and elevated postoperative calcitonin: Predictors of poor survival in medullary thyroid carcinoma
2015
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment
2009 Standout
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Is basal ultrasensitive measurement of calcitonin capable of substituting for the pentagastrin‐stimulation test?
2012
RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
2006
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Prospective Trial of Unilateral Surgery for Nonhereditary Medullary Thyroid Carcinoma in Patients without Germline RET Mutations
2002
Platelets: Guardians of Tumor Vasculature
2009
Platelets and cancer
2002
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and function
1982
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Correlation of Early Metastatic Response by123I-Metaiodobenzylguanidine Scintigraphy With Overall Response and Event-Free Survival in Stage IV Neuroblastoma
2003
Familial Medullary Thyroid Carcinoma: Clinical Variability and Low Aggressiveness Associated withRETMutation at Codon 804
2002
Risk and Penetrance of Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 2A Families with Mutations at Codon 634 of the RET Proto-Oncogene
1998
Improved Diagnostic Methods in the Follow-Up of Medullary Thyroid Carcinoma by Highly Specific Calcitonin Measurements*
2000
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Estimation of Risk of Inherited Medullary Thyroid Carcinoma in Apparent Sporadic Patients
2001
Triethylenetetramine-N,N,N‘,N‘‘,N‘‘‘,N‘‘‘-hexaacetic Acid (TTHA) and TTHA-Bis(butanamide) as Chelating Agents Relevant to Radiopharmaceutical Applications
1998
Role of prophylactic thyroidectomy in RET 790 familial medullary thyroid carcinoma
2011
A Phase II Trial of Imatinib Therapy for Metastatic Medullary Thyroid Carcinoma
2007
In Vivo Studies of Nanostructure‐Based Photosensitizers for Photodynamic Cancer Therapy
2014
Impact of Metaiodobenzylguanidine Scintigraphy on Assessing Response of High-Risk Neuroblastoma to Dose-Intensive Induction Chemotherapy
2003
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
New photosensitizers for photodynamic therapy
2016 Standout
Multiple Endocrine Neoplasia Type 2A in a Kindred With C634Y Mutation
2005
Cancer treatment and survivorship statistics, 2019
2019 Standout
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
The Role of Radiation Therapy in the Treatment of Medullary Thyroid Cancer
2010
Comparison of Calcium and Pentagastrin Tests for the Diagnosis and Follow-Up of Medullary Thyroid Cancer
2011
The Chemistry of Neutron Capture Therapy
1998 Standout
Lysosomal Consept of Platelet Secretion ‐ Revisited
1989
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
1998
Hypothermia-induced Reversible Platelet Dysfunction
1987 Standout
Guidelines for the management of thyroid cancer
2014 Standout
The role of platelet activation in tumor metastasis
2008
Long‐term Outcome of Reoperations for Medullary Thyroid Carcinoma
2008
Tumortyp- und tumorstadienorientiertes chirurgisches Konzept bei Karzinomen der Schilddrüse
2010
Medullary thyroid carcinoma in Hong Kong Chinese patients.
2005
Thyroid carcinoma
2003 Standout
Evidence‐based Approach to the Management of Sporadic Medullary Thyroid Carcinoma
2007
Dose translation from animal to human studies revisited
2007 Standout
Works of A Boneu being referenced
Prediction of Carboplatin Clearance From Standard Morphological and Biological Patient Characteristics
1995
Summary of the Standards, Options and Recommendations for the use of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDP-PET scanning) in oncology (2002)
2003
Biodistribution study of 99mTc‐labeled LDL in B16‐melanoma‐bearing mice. Visualization of a preferential uptake by the tumor
1993
Metastatic neuroblastoma in children older than one year: Prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system
1996
Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients
1998
Risk and Penetrance of Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 2A Families with Mutations at Codon 634 of theRETProto-Oncogene1
1998
Novel germline RET mutation segregating with papillary thyroid carcinomas
2001
Multiple Endocrine Neoplasia Type 2: Management of Patients and Subjects at Risk
1997
Indium-111 labeling of low density lipoproteins (LDL) with the DTPA-bis(stearylamide) for tumor localization: first imaging and biodistribution in B16 tumored mice
1996
Exhausted platelets in patients with malignant solid tumors without evidence of active consumption coagulopathy
1984
Indium-111–Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors
2008
[Prediction of carboplatin clearance from morphological and biological patient characteristics].
1995
[Early therapeutic management of patients genetically predisposed to medullary thyroid cancer].
1998
Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type IIa: Retrospective French Multicentric Study
1996
Further studies on the relationship between platelet buoyant density and platelet age
1982
Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients.
1998
Kinetics of platelet «populationså in the stationary state
1973